Harmony Biosciences
630 W. Germantown Pike
Suite 215
Plymouth Meeting
Pennsylvania
19462
United States
Tel: 484-539-9800
Website: https://www.harmonybiosciences.com/
About Harmony Biosciences
At Harmony Biosciences, we specialize in developing and delivering treatments for rare neurological diseases that others often overlook. We believe that when empathy and innovation meet, a better life can begin for people living with neurological diseases. Our team of experts from a wide variety of disciplines and experiences is driven by our shared conviction that innovative science translates into therapeutic possibilities for patients, who are at the heart of everything we do.
Company Ownership: Public
Stock Symbol: HRMY
LEADERSHIP
Interim CEO: Jeff M. Dayno, MD
CONNECT
113 articles about Harmony Biosciences
-
Following its Scorpion Capital controversy in March, Harmony Biosciences is seeking to deepen its pipeline with an acquisition of Zynerba Pharmaceuticals’ cannabinoid therapies for neuropsychiatric disorders.
-
HARMONY BIOSCIENCES TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC.
8/14/2023
Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced a definitive agreement to acquire Zynerba Pharmaceuticals, Inc.
-
HARMONY BIOSCIENCES ANNOUNCES $125 MILLION SHARE REPURCHASE PROGRAM
8/1/2023
Harmony Biosciences Holdings, Inc. today announced that its Board of Directors authorized the repurchase of up to $125 million of the Company's common stock.
-
Harmony Biosciences Reports Second Quarter 2023 Financial Results and Business Updates
8/1/2023
Harmony Biosciences Holdings, Inc. (“Harmony” or the “Company”) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today reported financial results and business updates for the quarter ended June 30, 2023.
-
HARMONY BIOSCIENCES ENTERS INTO $185 MILLION TERM LOAN FACILITY
7/27/2023
Harmony Biosciences Holdings, Inc. today announced it has entered into a new $185 million senior secured term loan facility with a bank syndicate.
-
Harmony Biosciences Announces Funding for Unique Community Initiatives Through its Patients and Progress at the Heart Awards Programs
7/25/2023
Harmony Biosciences selected the latest round of nonprofit organizations for its Patients at the Heart and Progress at the Heart awards, which provide funding toward interdisciplinary community initiatives that address complex challenges facing people living with sleep disorders and rare neurological diseases.
-
HARMONY BIOSCIENCES ANNOUNCES PLANS TO INITIATE PHASE 3 REGISTRATIONAL STUDY OF PITOLISANT IN PRADER-WILLI SYNDROME
7/20/2023
Harmony Biosciences Holdings, Inc. has successfully completed an End-of-Phase 2 meeting with FDA regarding its clinical development plan evaluating pitolisant as a potential treatment for excessive daytime sleepiness (EDS) in patients ages six and older with Prader-Willi syndrome (PWS).
-
HARMONY BIOSCIENCES TO REPORT SECOND QUARTER 2023 FINANCIAL RESULTS ON AUGUST 1, 2023
7/18/2023
Harmony Biosciences Holdings, Inc. today announced that it will report second quarter 2023 financial results on Tuesday, August 1, 2023, before the open of the U.S. financial markets.
-
HARMONY BIOSCIENCES ANNOUNCES POSITIVE PHASE 2 SIGNAL DETECTION STUDY EVALUATING PITOLISANT FOR EXCESSIVE DAYTIME SLEEPINESS IN PRADER-WILLI SYNDROME AT SLEEP 2023
6/6/2023
Harmony Biosciences Holdings, Inc. today announced the presentation of safety and efficacy data from a Phase 2 proof-of-concept study evaluating pitolisant for the treatment of excessive daytime sleepiness (EDS) in people with Prader-Willi syndrome.
-
HARMONY BIOSCIENCES TO PARTICIPATE IN GOLDMAN SACHS 44th ANNUAL GLOBAL HEALTHCARE CONFERENCE
5/30/2023
Harmony Biosciences Holdings, Inc. today announced that Harmony's management team will participate in a fireside chat at the upcoming Goldman Sachs 44th Annual Global Healthcare Conference in Dana Point, CA on Tuesday, June 13, 2023, at 2:00 p.m. PT/ 5:00 p.m. ET.
-
HARMONY BIOSCIENCES TO PRESENT NEW WAKIX® (PITOLISANT) SAFETY AND EFFICACY DATA AT SLEEP 2023 ANNUAL MEETING
5/10/2023
Harmony Biosciences Holdings, Inc. today announced that new safety and efficacy data from a Phase 2 proof-of-concept study evaluating pitolisant for the treatment of excessive daytime sleepiness in patients with Prader-Willi syndrome (PWS) will be highlighted as a poster presentation during a late-breaking abstract session at the 37th Annual Meeting of the Associated Professional Sleep Societies (APSS), known as "SLEEP 2023," in Indianapolis from June 3-7.
-
Harmony Biosciences Reports First Quarter 2023 Financial Results and Business Updates
5/2/2023
Harmony Biosciences Holdings, Inc. (“Harmony” or the “Company”) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today reported financial results and business updates for the quarter ended March 31, 2023.
-
HARMONY BIOSCIENCES ANNOUNCES JEFFREY M. DAYNO, M.D. APPOINTED PRESIDENT & CHIEF EXECUTIVE OFFICER
4/24/2023
Dr. Dayno joins Harmony Biosciences Board of Directors.
-
HARMONY BIOSCIENCES TO REPORT FIRST QUARTER 2023 FINANCIAL RESULTS ON MAY 2, 2023
4/20/2023
Harmony Biosciences Holdings, Inc. today announced that it will report first quarter 2023 financial results on Tuesday, May 2, 2023, before the open of the U.S. financial markets.
-
Citing reports of “alarming toxicity” among other accusations, short-seller Scorpion Capital will file a Citizen’s Petition with the FDA to have its approval of Wakix withdrawn.
-
HARMONY BIOSCIENCES ANNOUNCES ACCELERATED TIMELINE FOR PHASE 3 INTUNE STUDY IN IDIOPATHIC HYPERSOMNIA
3/29/2023
Harmony Biosciences Holdings, Inc. today announced an accelerated timeline for completing its Phase 3 INTUNE study evaluating the safety and efficacy of pitolisant in adult patients with idiopathic hypersomnia (IH).
-
HARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES - March 6, 2023
3/6/2023
Harmony Biosciences Holdings, Inc. today announced that Harmony's management team will participate in the following upcoming investor conferences.
-
Harmony Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
2/21/2023
Harmony Biosciences today reported financial results and business updates for the fourth quarter and full year ended December 31, 2022.
-
HARMONY BIOSCIENCES TO REPORT FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS ON FEBRUARY 21, 2023
2/7/2023
Harmony Biosciences Holdings, Inc. today announced that it will report fourth quarter and full year 2022 financial results on Tuesday, February 21, 2023, before the open of the U.S. financial markets.
-
Harmony Biosciences Appoints Jeffrey M. Dayno, MD as Interim CEO and Expands Role of Jeff Aronin to Executive Chairman
1/6/2023
Harmony Biosciences Holdings, Inc., a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, announced that John C. Jacobs is stepping down as President and Chief Executive Officer and a member of the Board of Directors to pursue another opportunity.